The new statutory system of value-based pricing being planned in the U.K. for branded drugs could endanger future investments in biotechnology, the BioIndustry Association said. The Department of Health is making the shift next year, and the assessment of new drug prices will be handled by the National Institute for Health and Care Excellence. "The perception of the U.K. as a market for innovative products has an important bearing not only on the global investment decisions of multinational biopharmaceutical companies, but also upon private investment to support early-stage bioscience companies," BIA CEO Steve Bates said.

Full Story:
PharmaTimes (U.K.)

Related Summaries